About iovance biotherapeutics inc. - IOVA
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
IOVA At a Glance
Iovance Biotherapeutics, Inc.
825 Industrial Road
San Carlos, California 94070
| Phone | 1-650-260-7120 | Revenue | 263.50M | |
| Industry | Biotechnology | Net Income | -390,978,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 60.603% | |
| Fiscal Year-end | 12 / 2026 | Employees | 975 | |
| View SEC Filings |
IOVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 3.702 |
| Price to Book Ratio | 1.61 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.075 |
| Enterprise Value to Sales | 2.763 |
| Total Debt to Enterprise Value | 0.068 |
IOVA Efficiency
| Revenue/Employee | 270,258.462 |
| Income Per Employee | -401,003.077 |
| Receivables Turnover | 3.196 |
| Total Asset Turnover | 0.289 |
IOVA Liquidity
| Current Ratio | 3.20 |
| Quick Ratio | 2.826 |
| Cash Ratio | 2.146 |
IOVA Profitability
| Gross Margin | 20.637 |
| Operating Margin | -151.123 |
| Pretax Margin | -149.164 |
| Net Margin | -148.378 |
| Return on Assets | -42.88 |
| Return on Equity | -55.498 |
| Return on Total Capital | -52.268 |
| Return on Invested Capital | -52.174 |
IOVA Capital Structure
| Total Debt to Total Equity | 7.078 |
| Total Debt to Total Capital | 6.61 |
| Total Debt to Total Assets | 5.415 |
| Long-Term Debt to Equity | 6.356 |
| Long-Term Debt to Total Capital | 5.936 |